On Tuesday, Bahrain’s Covid-19 cases reached 1,000 for the first time in two months. The Ministry of Health declared 1,008 cases yesterday and advised caution.
The pandemic war is not done, according to a senior doctor, and progress must be maintained.
The increase in Covid-19 cases occurs when the Kingdom is on high alert due to the spread of monkeypox.
The Ministry of Health’s vaccination milestones and preventive programs are responsible for the Kingdom’s recent win against the pandemic.
Johnson Ad26.COV2.S, Gamaleya Sputnik Light, Pfizer/BioNTech Comirnaty, ValnevaVLA2001, Covaxin, Gamaleya Sputnik V, Bharat Biotech Sinopharm Covilo, and Johnson and Covishield AstraZeneca, have all been approved by the Kingdom.
Bahrain is the first country to have the French Covid-19 vaccine approved, received, and administered. The frequency of Covid infection, ICU hospitalizations, and mortality among Sinopharm vaccination users in the Kingdom remained high, according to Nature Magazine.
Dr. Sid Mukherjee looked at the Covid-19 results from a statewide database, taking into account four immunizations to reduce pandemic risk.
Despite the fact that all four vaccines reduced COVID-19-related hospitalizations, ICU admissions, and deaths, Sinopharm vaccine users had a higher risk of SARS-CoV-2 infection, hospitalizations, and ICU admissions than non-Sinopharm vaccine users.